Adaptation and growth characteristics of influenza virus at 25 degrees c - PubMed (original) (raw)

. 1967 Feb 11;213(5076):612-4.

doi: 10.1038/213612a0.

• PMID: 6040602
• DOI: 10.1038/213612a0

Adaptation and growth characteristics of influenza virus at 25 degrees c

H F Maassab. Nature. 1967.

No abstract available

PubMed Disclaimer

Similar articles

• Investigations on the effect of the host on certain activities of influenza virus.
  Rathová V, Kocisková D, Borecký L. Rathová V, et al. Acta Virol. 1968 Sep;12(5):420-7. Acta Virol. 1968. PMID: 4386634 No abstract available.
• Studies on pathogenicity and immunogenicity of cold adapted variants of influenza virus.
  Brydak L. Brydak L. Acta Microbiol Pol. 1982;31(3-4):287-92. Acta Microbiol Pol. 1982. PMID: 6189378
• Laboratory differences between the WS strain of influenza A virus and its neurotropic variants.
  Hobson D, Gould EA, Flockton HI, Gregory MG. Hobson D, et al. Br J Exp Pathol. 1968 Oct;49(5):516-24. Br J Exp Pathol. 1968. PMID: 5727753 Free PMC article. No abstract available.
• The influence of egg weight on the propagation of Newcastle disease, influenza, and CELO viruses in embryonating eggs.
  Ablashi DV, Chang PW, Yates VJ. Ablashi DV, et al. Avian Dis. 1966 May;10(2):224-30. Avian Dis. 1966. PMID: 6007132 No abstract available.

Cited by

• Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial.
  Piedra PA, Gaglani MJ, Riggs M, Herschler G, Fewlass C, Watts M, Kozinetz C, Hessel C, Glezen WP. Piedra PA, et al. Pediatrics. 2005 Sep;116(3):e397-407. doi: 10.1542/peds.2004-2258. Pediatrics. 2005. PMID: 16140685 Free PMC article. Clinical Trial.
• Live attenuated influenza virus vaccines by computer-aided rational design.
  Mueller S, Coleman JR, Papamichail D, Ward CB, Nimnual A, Futcher B, Skiena S, Wimmer E. Mueller S, et al. Nat Biotechnol. 2010 Jul;28(7):723-6. doi: 10.1038/nbt.1636. Epub 2010 Jun 13. Nat Biotechnol. 2010. PMID: 20543832 Free PMC article.
• Adenoviral-Vectored Centralized Consensus Hemagglutinin Vaccine Provides Broad Protection against H2 Influenza a Virus.
  Petro-Turnquist EM, Bullard BL, Pekarek MJ, Weaver EA. Petro-Turnquist EM, et al. Vaccines (Basel). 2022 Jun 10;10(6):926. doi: 10.3390/vaccines10060926. Vaccines (Basel). 2022. PMID: 35746534 Free PMC article.
• New Vaccine Design and Delivery Technologies.
  Kanekiyo M, Ellis D, King NP. Kanekiyo M, et al. J Infect Dis. 2019 Apr 8;219(Suppl_1):S88-S96. doi: 10.1093/infdis/jiy745. J Infect Dis. 2019. PMID: 30715361 Free PMC article.
• Novel Approaches for The Development of Live Attenuated Influenza Vaccines.
  Blanco-Lobo P, Nogales A, Rodríguez L, Martínez-Sobrido L. Blanco-Lobo P, et al. Viruses. 2019 Feb 22;11(2):190. doi: 10.3390/v11020190. Viruses. 2019. PMID: 30813325 Free PMC article. Review.

MeSH terms

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Other Literature Sources

  • The Lens - Patent Citations Database